Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

G. Ferrandina, F. O. Ranelletti, L. Lauriola, F. Fanfani, F. Legge, M. Mottolese, M. R. Nicotra, P. G. Natali, V. H. Zakut, G. Scambia

Research output: Contribution to journalArticle

Abstract

Objectives. Cyclooxygenase-2 (COX-2) seems to be involved in critical steps of cancer onset and progression. Abnormalities of epidermal growth factor receptor (EGFR)and Her-2/neu have been actively investigated in ovarian cancer and associated with unfavorable clinical outcome. The involvement of COX-2 in ErbB family pathways has been proposed. We investigated by immunohistochemistry the expression of COX-2, EGFR, and Her-2/neu in a series of advanced primary ovarian cancers. Methods. The study included 76 consecutive stage IIIC-IV ovarian cancer patients with measurable disease after first surgery. Immunohistochemistry was performed on paraffin-embedded sections with rabbit antiserum against COX-2, murine monoclonal antibody (MoAb) 300G9 against Her-2/neu, and monoclonal antibody 108 against EGFR. Results. No association among COX-2, EGFR, and HER-2/neu was found. COX-2 positivity was found in a statistically significant higher percentage of unresponsive cases (80.0%) than in patients responding to chemotherapy (35.7%) (P = 0.0008). The association between COX-2 positivity and poor chance of response to treatment was retained in multivariate analysis. In the subgroup of patients who underwent explorative laparotomy COX-2-positive cases showed a shorter overall survival (P = 0.049). Conclusions. COX-2 could represent a possible new marker of sensitivity to platin-based chemotherapy in ovarian cancer. The lack of association of COX-2 with EGFR or Her-2/neu suggests that the ability of COX-2 to predict tumor sensitivity to chemotherapy is not dependent on EGFR or Her-2/neu status and could be independently associated with prognosis. In this context, the availability of agents able to specifically interfere with COX-2, Her-2/neu, or EGFR tyrosine kinase is of potential interest.

Original languageEnglish
Pages (from-to)305-310
Number of pages6
JournalGynecologic Oncology
Volume85
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Cyclooxygenase 2
Epidermal Growth Factor Receptor
Ovarian Neoplasms
Drug Therapy
Immunohistochemistry
Monoclonal Antibodies
Aptitude
Paraffin
Protein-Tyrosine Kinases
Laparotomy
Immune Sera
Neoplasms
Multivariate Analysis
Rabbits

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. / Ferrandina, G.; Ranelletti, F. O.; Lauriola, L.; Fanfani, F.; Legge, F.; Mottolese, M.; Nicotra, M. R.; Natali, P. G.; Zakut, V. H.; Scambia, G.

In: Gynecologic Oncology, Vol. 85, No. 2, 2002, p. 305-310.

Research output: Contribution to journalArticle

Ferrandina, G, Ranelletti, FO, Lauriola, L, Fanfani, F, Legge, F, Mottolese, M, Nicotra, MR, Natali, PG, Zakut, VH & Scambia, G 2002, 'Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer', Gynecologic Oncology, vol. 85, no. 2, pp. 305-310. https://doi.org/10.1006/gyno.2002.6620
Ferrandina, G. ; Ranelletti, F. O. ; Lauriola, L. ; Fanfani, F. ; Legge, F. ; Mottolese, M. ; Nicotra, M. R. ; Natali, P. G. ; Zakut, V. H. ; Scambia, G. / Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. In: Gynecologic Oncology. 2002 ; Vol. 85, No. 2. pp. 305-310.
@article{8e09eab1622445e8b12b234c04350b9b,
title = "Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer",
abstract = "Objectives. Cyclooxygenase-2 (COX-2) seems to be involved in critical steps of cancer onset and progression. Abnormalities of epidermal growth factor receptor (EGFR)and Her-2/neu have been actively investigated in ovarian cancer and associated with unfavorable clinical outcome. The involvement of COX-2 in ErbB family pathways has been proposed. We investigated by immunohistochemistry the expression of COX-2, EGFR, and Her-2/neu in a series of advanced primary ovarian cancers. Methods. The study included 76 consecutive stage IIIC-IV ovarian cancer patients with measurable disease after first surgery. Immunohistochemistry was performed on paraffin-embedded sections with rabbit antiserum against COX-2, murine monoclonal antibody (MoAb) 300G9 against Her-2/neu, and monoclonal antibody 108 against EGFR. Results. No association among COX-2, EGFR, and HER-2/neu was found. COX-2 positivity was found in a statistically significant higher percentage of unresponsive cases (80.0{\%}) than in patients responding to chemotherapy (35.7{\%}) (P = 0.0008). The association between COX-2 positivity and poor chance of response to treatment was retained in multivariate analysis. In the subgroup of patients who underwent explorative laparotomy COX-2-positive cases showed a shorter overall survival (P = 0.049). Conclusions. COX-2 could represent a possible new marker of sensitivity to platin-based chemotherapy in ovarian cancer. The lack of association of COX-2 with EGFR or Her-2/neu suggests that the ability of COX-2 to predict tumor sensitivity to chemotherapy is not dependent on EGFR or Her-2/neu status and could be independently associated with prognosis. In this context, the availability of agents able to specifically interfere with COX-2, Her-2/neu, or EGFR tyrosine kinase is of potential interest.",
author = "G. Ferrandina and Ranelletti, {F. O.} and L. Lauriola and F. Fanfani and F. Legge and M. Mottolese and Nicotra, {M. R.} and Natali, {P. G.} and Zakut, {V. H.} and G. Scambia",
year = "2002",
doi = "10.1006/gyno.2002.6620",
language = "English",
volume = "85",
pages = "305--310",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

AU - Ferrandina, G.

AU - Ranelletti, F. O.

AU - Lauriola, L.

AU - Fanfani, F.

AU - Legge, F.

AU - Mottolese, M.

AU - Nicotra, M. R.

AU - Natali, P. G.

AU - Zakut, V. H.

AU - Scambia, G.

PY - 2002

Y1 - 2002

N2 - Objectives. Cyclooxygenase-2 (COX-2) seems to be involved in critical steps of cancer onset and progression. Abnormalities of epidermal growth factor receptor (EGFR)and Her-2/neu have been actively investigated in ovarian cancer and associated with unfavorable clinical outcome. The involvement of COX-2 in ErbB family pathways has been proposed. We investigated by immunohistochemistry the expression of COX-2, EGFR, and Her-2/neu in a series of advanced primary ovarian cancers. Methods. The study included 76 consecutive stage IIIC-IV ovarian cancer patients with measurable disease after first surgery. Immunohistochemistry was performed on paraffin-embedded sections with rabbit antiserum against COX-2, murine monoclonal antibody (MoAb) 300G9 against Her-2/neu, and monoclonal antibody 108 against EGFR. Results. No association among COX-2, EGFR, and HER-2/neu was found. COX-2 positivity was found in a statistically significant higher percentage of unresponsive cases (80.0%) than in patients responding to chemotherapy (35.7%) (P = 0.0008). The association between COX-2 positivity and poor chance of response to treatment was retained in multivariate analysis. In the subgroup of patients who underwent explorative laparotomy COX-2-positive cases showed a shorter overall survival (P = 0.049). Conclusions. COX-2 could represent a possible new marker of sensitivity to platin-based chemotherapy in ovarian cancer. The lack of association of COX-2 with EGFR or Her-2/neu suggests that the ability of COX-2 to predict tumor sensitivity to chemotherapy is not dependent on EGFR or Her-2/neu status and could be independently associated with prognosis. In this context, the availability of agents able to specifically interfere with COX-2, Her-2/neu, or EGFR tyrosine kinase is of potential interest.

AB - Objectives. Cyclooxygenase-2 (COX-2) seems to be involved in critical steps of cancer onset and progression. Abnormalities of epidermal growth factor receptor (EGFR)and Her-2/neu have been actively investigated in ovarian cancer and associated with unfavorable clinical outcome. The involvement of COX-2 in ErbB family pathways has been proposed. We investigated by immunohistochemistry the expression of COX-2, EGFR, and Her-2/neu in a series of advanced primary ovarian cancers. Methods. The study included 76 consecutive stage IIIC-IV ovarian cancer patients with measurable disease after first surgery. Immunohistochemistry was performed on paraffin-embedded sections with rabbit antiserum against COX-2, murine monoclonal antibody (MoAb) 300G9 against Her-2/neu, and monoclonal antibody 108 against EGFR. Results. No association among COX-2, EGFR, and HER-2/neu was found. COX-2 positivity was found in a statistically significant higher percentage of unresponsive cases (80.0%) than in patients responding to chemotherapy (35.7%) (P = 0.0008). The association between COX-2 positivity and poor chance of response to treatment was retained in multivariate analysis. In the subgroup of patients who underwent explorative laparotomy COX-2-positive cases showed a shorter overall survival (P = 0.049). Conclusions. COX-2 could represent a possible new marker of sensitivity to platin-based chemotherapy in ovarian cancer. The lack of association of COX-2 with EGFR or Her-2/neu suggests that the ability of COX-2 to predict tumor sensitivity to chemotherapy is not dependent on EGFR or Her-2/neu status and could be independently associated with prognosis. In this context, the availability of agents able to specifically interfere with COX-2, Her-2/neu, or EGFR tyrosine kinase is of potential interest.

UR - http://www.scopus.com/inward/record.url?scp=0036098022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036098022&partnerID=8YFLogxK

U2 - 10.1006/gyno.2002.6620

DO - 10.1006/gyno.2002.6620

M3 - Article

C2 - 11972392

AN - SCOPUS:0036098022

VL - 85

SP - 305

EP - 310

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -